Tecentriq® (atezolizumab) - Risk Of Immune-related Myositis

TECENTRIQ® (atezolizumab) Recall Summary Tecentriq, a cancer medication, is being recalled across Canada due to a risk of immune-related myositis, a condition where the immune system attacks muscle tissue. This recall affects patients who have received or may receive this drug for cancer treatment. The manufacturer identified this safety concern related to how the drug affects the immune system.

Reason

Product safety

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2019-03-13

Status

Ongoing

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/88ab899f-0b79-46e9-b920-57c658712b31